Skip to content

PROPANC BIOPHARMA, INC.: 10-Q filed 2024-05-15

What PROPANC BIOPHARMA, INC. reported in its quarterly report filed 2024-05-15 (fiscal Q3 2024): 37 published measures, 114 facts as tagged in accession 0001493152-24-019940.

This filing

Form
10-Q (quarterly report)
Filed
2024-05-15
Fiscal period
fiscal Q3 2024
Accession
0001493152-24-019940 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROPANC BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-03-3137,337USD
At 2023-06-3060,328USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-03-313,736,854USD
At 2023-06-303,177,507USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-03-31-3,699,517USD
At 2023-12-31-3,563,599USD
At 2023-09-30-2,989,259USD
At 2023-06-30-3,117,179USD
At 2023-03-31-2,941,414USD
At 2022-12-31-2,915,417USD
At 2022-09-30-2,767,535USD
At 2022-06-30-3,023,649USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-526,700USD91
2023-07-01 to 2024-03-31-1,461,950USD275
2023-10-01 to 2023-12-31-584,384USD92
2023-07-01 to 2023-09-30-350,866USD92
2023-01-01 to 2023-03-31-809,809USD90
2022-07-01 to 2023-03-31-1,912,522USD274
2022-10-01 to 2022-12-31-485,418USD92
2022-07-01 to 2022-09-30-617,295USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-07-01 to 2024-03-31-675,152USD275
2022-07-01 to 2023-03-31-927,278USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-07-01 to 2024-03-31690,920USD275
2022-07-01 to 2023-03-311,013,719USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-03-31-66,339,642USD
At 2023-06-30-64,684,732USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-03-3159,639,618shares91
2023-07-01 to 2024-03-3131,378,516shares275
2023-01-01 to 2023-03-311,924,074shares90
2022-07-01 to 2023-03-311,115,848shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-03-3159,639,618shares91
2023-07-01 to 2024-03-3131,378,516shares275
2023-01-01 to 2023-03-311,924,074shares90
2022-07-01 to 2023-03-311,115,848shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-0.01USD/shares91
2023-07-01 to 2024-03-31-0.05USD/shares275
2023-01-01 to 2023-03-31-0.42USD/shares90
2022-07-01 to 2023-03-31-2.08USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-0.01USD/shares91
2023-07-01 to 2024-03-31-0.05USD/shares275
2023-01-01 to 2023-03-31-0.42USD/shares90
2022-07-01 to 2023-03-31-2.08USD/shares274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-275USD91
2023-07-01 to 2024-03-31-128,895USD275
2023-01-01 to 2023-03-31-1,716USD90
2022-07-01 to 2023-03-31-131,037USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-06-30302USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-07-01 to 2023-03-312,408USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-420,867USD91
2023-07-01 to 2024-03-31-1,276,150USD275
2023-01-01 to 2023-03-31-386,209USD90
2022-07-01 to 2023-03-31-1,567,043USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-03-3112,855USD
At 2023-06-3019,039USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-01-01 to 2024-03-31133,141USD91
2023-07-01 to 2024-03-31575,837USD275
2023-01-01 to 2023-03-31157,208USD90
2022-07-01 to 2023-03-31418,579USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-03-313,687,984USD
At 2023-06-303,158,229USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-03-311,187,714USD
At 2023-06-30966,718USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-01-01 to 2024-03-31420,867USD91
2023-07-01 to 2024-03-311,276,150USD275
2023-01-01 to 2023-03-31386,209USD90
2022-07-01 to 2023-03-311,567,043USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-03-3165,448USD91
2023-07-01 to 2024-03-31195,712USD275
2023-01-01 to 2023-03-3166,020USD90
2022-07-01 to 2023-03-31242,223USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-03-31109,706,411shares
At 2023-06-306,031,250shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-03-3161,237,446USD
At 2023-06-3060,311,502USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2024-03-311,339,450USD
At 2023-06-301,294,876USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2024-03-31582,951USD
At 2023-06-30390,539USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-03-3124,868USD
At 2023-06-3025,432USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-03-3124,868USD
At 2023-06-3025,130USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-03-311,368USD
At 2023-06-306,125USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-526,975USD91
2023-07-01 to 2024-03-31-1,590,845USD275
2023-01-01 to 2023-03-31-811,525USD90
2022-07-01 to 2023-03-31-2,043,559USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-437,120USD91
2023-07-01 to 2024-03-31-1,610,336USD275
2023-01-01 to 2023-03-31-769,195USD90
2022-07-01 to 2023-03-31-2,261,881USD274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-542,500USD91
2023-07-01 to 2024-03-31-1,654,910USD275
2023-01-01 to 2023-03-31-809,809USD90
2022-07-01 to 2023-03-31-2,321,079USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31348,841USD91
2023-07-01 to 2024-03-311,060,854USD275
2023-01-01 to 2023-03-31311,824USD90
2022-07-01 to 2023-03-311,302,576USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-01-01 to 2024-03-3149USD91
2023-07-01 to 2024-03-31297USD275
2023-01-01 to 2023-03-31450USD90
2022-07-01 to 2023-03-311,345USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-106,108USD91
2023-07-01 to 2024-03-31-314,695USD275
2023-01-01 to 2023-03-31-425,316USD90
2022-07-01 to 2023-03-31-476,516USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-07-01 to 2024-03-317,559USD275
2022-07-01 to 2023-03-311,544USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-07-01 to 2024-03-3111,082USD275
2022-07-01 to 2023-03-3124,711USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-07-01 to 2024-03-31242,466USD275
2022-07-01 to 2023-03-3127,953USD274

Inspect the source

Entity
PROPANC BIOPHARMA, INC. / CIK 0001517681
Captured
2026-09-20T09:14:07.933Z
SEC response SHA-256
4f6eac6bf72e7f988a9a94ea85589b445974414449c4b417540ed20477181487

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001517681.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))